Comparison of combined treatment with desmopressin plus oxybutynin and desmopressin plus tolterodine in treatment of children with primary nocturnal enuresis.

Abstract

Introduction: Nocturnal enuresis (enuresis) is one of the most common developmental problems of childhood, which has often a familial basis, causes mental and psychological damage to the child and disrupts family solace. Objectives: In this study, we compared therapeutic effects of combination therapy of desmopressin plus oxybutynin with desmopressin plus tolterodine, in the treatment of children with primary nocturnal enuresis. Patients and Methods: The present study is a clinical trial study, where 59 patients with primary nocturnal enuresis in the age range of 5 to 14 years old were selected from the visitors of nephrology clinic of Dr. Sheikh pediatrics hospital (Mashhad, Iran). Patients were divided into 2 treatment groups where the first group received combined therapy with desmopressin and oxybutynin, and the second group received combined therapy with desmopressin and tolterodine. Data was analyzed using SPSS 16 software and descriptive and analytical statistics (chi-square test). Results: The mean of age of patients in total was 2.55 ± 7.90 years. In the treatment group with desmopressin and oxybutynin, 26 of 30 patients (86.7%) achieved a complete remission and 4 patients (13.3%) still suffered from enuresis during a 3-month evaluation. The comparison of 2 groups, in terms of the outcome of the 3-month treatment, showed significant differences between the remission and recovery of 2 groups, where the recovery in the group with desmopressin plus tolterodine was higher than the group with desmopressin plus oxybutynin (P = 0.001). Conclusion: The results showed that combined treatment with desmopressin plus tolterodine performs better than desmopressin plus oxybutynin .